GSK Shares Drop 2.75% as Tax Burden and Legal Reprieve Weigh on Surging 75% Volume, Ranking 373rd

Market Snapshot

Shares of GlaxoSmithKline (GSK) fell 2.75% on March 5, 2026, with a trading volume of $0.38 billion, reflecting a 75.41% increase from the previous day. The stock ranked 373rd in terms of volume among all listed equities, indicating moderate investor activity. Despite the legal and regulatory developments detailed in recent news, the price decline suggests market skepticism or a broader sector correction in pharmaceuticals.

Key Drivers

The dismissal of a securities fraud class action lawsuit over Zantac-related allegations provided a short-term legal reprieve for GSK. The U.S. District Court for the Eastern District of Pennsylvania ruled that the case was filed too late, citing publicly available information that should have prompted claims earlier. While this outcome reduces immediate legal exposure, the court’s reasoning underscores the importance of timely litigation, which may limit the company’s long-term liability. Investors may have anticipated a more favorable resolution, but the dismissal likely failed to offset broader concerns about the stock.

A significant headwind emerged from global minimum tax regulations, which reduced GSK’s tax incentives by £169 million ($226 million) in 2025. The company classified this as a Pillar Two tax expense in its annual report, reflecting the OECD’s 15% minimum corporate tax framework. This non-cash charge directly impacts profitability and earnings per share, potentially dampening investor sentiment. The tax adjustment, combined with the pharmaceutical sector’s broader exposure to regulatory pressures, may have contributed to the stock’s decline.

Positive developments in GSK’s therapeutic pipeline partially offset these challenges. The company secured European Commission and Japanese Ministry of Health approvals for depemokimab (EXDENSUR) as an add-on treatment for severe chronic rhinosinusitis with nasal polyps (CRSwNP). These regulatory milestones highlight GSK’s progress in addressing unmet medical needs and expanding its respiratory portfolio. However, the U.S. FDA’s rejection of the CRSwNP indication for depemokimab, without detailed reasoning, introduces uncertainty. GSK’s continued confidence in the therapy’s potential suggests it remains committed to engaging with regulators, but the lack of U.S. approval could delay revenue streams.

Collaborative efforts with biotech firms also emerged as a growth driver. GSK entered a strategic partnership with CAMP4 Therapeutics, receiving $17.5 million upfront for RNA-based therapeutic discoveries. Additionally, a $24.8 million payment from SCYNEXIS in Q4 2025, tied to the transfer of the BREXAFEMME New Drug Application, underscores GSK’s role in advancing antifungal therapies. While these partnerships bolster innovation, the associated cash outflows and ongoing clinical trials may weigh on near-term financial flexibility.

The interplay of these factors—legal clarity, regulatory challenges, pipeline advancements, and collaborative investments—paints a complex picture for GSK. While the dismissal of the Zantac lawsuit and international approvals offer strategic advantages, the tax burden and unmet U.S. regulatory expectations highlight structural risks. Investors appear to be recalibrating their expectations, with the stock price reflecting a balance between these competing dynamics.